FRIDAY, Oct. 24, 2014 (HealthDay News) -- Obizur (antihemophilic factor recombinant) has been approved to treat a rare, non-inherited form of hemophilia in adults.
Unlike the more common form of hemophilia that's inherited and affects males, acquired hemophilia affects both males and females. The rarer form of the blood disorder occurs when the body's immune system attacks a protein that's necessary for normal blood clotting.
About half the cases of acquired hemophilia are related to other medical conditions, such as pregnancy, cancer or use of certain medications. But about half of cases have no known cause, the FDA said Friday in a news release.
Obizur was evaluated in clinical studies involving 29 adults with acquired hemophilia, who were given Obizur to treat a serious bleeding episode. The trial didn't identify any safety concerns, the FDA said.
Obizur is manufactured by Baxter Healthcare, based in Westlake Village, Calif.
More information
Visit the FDA to learn more.
Copyright © 2014 HealthDay. All rights reserved.
